At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 70 enrolled
Drug / intervention
DA-3002drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open, Multi-Center, Controlled, Randomized Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-3002(Recombinant Humn Growth Hormone)Treatment in Children With Idiopathic Short Stature
In Brief
A Phase 3 clinical trial evaluating DA-3002 for Idiopathic Short Stature. Completed, enrolled 70 participants.
Detailed Summary
Growth hormone therapy will improve the height of idiopathic short statured children. DA-3002(Recombinant Human Growth hormone)treated group for 26 weeks, will be compared to non-treatment group in efficacy and safety.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Short Stature
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2012
First PostedFeb 2013
Primary CompletionApr 2014
TodayJul 2026
First PostedFeb 8, 2013
Enrollment StartFeb 1, 2012
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 13.4 years ago
Interventions
DA-3002drug